| pubmed-article:8722838 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8722838 | lifeskim:mentions | umls-concept:C0001175 | lld:lifeskim |
| pubmed-article:8722838 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8722838 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:8722838 | lifeskim:mentions | umls-concept:C0085436 | lld:lifeskim |
| pubmed-article:8722838 | lifeskim:mentions | umls-concept:C1273870 | lld:lifeskim |
| pubmed-article:8722838 | lifeskim:mentions | umls-concept:C0725066 | lld:lifeskim |
| pubmed-article:8722838 | lifeskim:mentions | umls-concept:C0332185 | lld:lifeskim |
| pubmed-article:8722838 | lifeskim:mentions | umls-concept:C0449435 | lld:lifeskim |
| pubmed-article:8722838 | pubmed:dateCreated | 1996-10-24 | lld:pubmed |
| pubmed-article:8722838 | pubmed:abstractText | The optimum regimen for the treatment of cryptococcal meningitis in patients with AIDS is still not totally clear. The triazoles fluconazole and itraconazole are associated with response rates of 50%-60%. Amphotericin B appears to be associated with a more rapid clearance of organisms, and there are some data suggesting that initial therapy with amphotericin B is preferable to that with triazoles; however, this finding has not been definitively shown in large comparative trials. Results of a recently completed large trial suggested that initial treatment with amphotericin B followed by triazole therapy is associated with an acute mortality rate (approximately 6%) that is substantially less than that in previous studies. Relapse is common (20%-60% of cases) if the patient does not receive chronic suppressive therapy. The drug of choice for maintenance therapy is fluconazole (200 mg/d). A recent trial showed that fluconazole was superior to itraconazole (200 mg/d) as suppressive therapy. Prophylactic use of fluconazole (200 mg/d) significantly decreases the incidence of cryptococcosis and mucosal candidiasis, especially in patients with CD4 cell counts of < 50/mm3. However, because of the lack of a survival benefit and the risk of the selection effect on fluconazole-resistant Candida, it is difficult to make the recommendation of routine prophylaxis with fluconazole for all patients with AIDS; the decision to use prophylaxis should be based on more selective criteria. | lld:pubmed |
| pubmed-article:8722838 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8722838 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8722838 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8722838 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8722838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8722838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8722838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8722838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8722838 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8722838 | pubmed:month | May | lld:pubmed |
| pubmed-article:8722838 | pubmed:issn | 1058-4838 | lld:pubmed |
| pubmed-article:8722838 | pubmed:author | pubmed-author:PowderlyW GWG | lld:pubmed |
| pubmed-article:8722838 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8722838 | pubmed:volume | 22 Suppl 2 | lld:pubmed |
| pubmed-article:8722838 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8722838 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8722838 | pubmed:pagination | S119-23 | lld:pubmed |
| pubmed-article:8722838 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8722838 | pubmed:meshHeading | pubmed-meshheading:8722838-... | lld:pubmed |
| pubmed-article:8722838 | pubmed:meshHeading | pubmed-meshheading:8722838-... | lld:pubmed |
| pubmed-article:8722838 | pubmed:meshHeading | pubmed-meshheading:8722838-... | lld:pubmed |
| pubmed-article:8722838 | pubmed:meshHeading | pubmed-meshheading:8722838-... | lld:pubmed |
| pubmed-article:8722838 | pubmed:meshHeading | pubmed-meshheading:8722838-... | lld:pubmed |
| pubmed-article:8722838 | pubmed:meshHeading | pubmed-meshheading:8722838-... | lld:pubmed |
| pubmed-article:8722838 | pubmed:meshHeading | pubmed-meshheading:8722838-... | lld:pubmed |
| pubmed-article:8722838 | pubmed:meshHeading | pubmed-meshheading:8722838-... | lld:pubmed |
| pubmed-article:8722838 | pubmed:meshHeading | pubmed-meshheading:8722838-... | lld:pubmed |
| pubmed-article:8722838 | pubmed:meshHeading | pubmed-meshheading:8722838-... | lld:pubmed |
| pubmed-article:8722838 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8722838 | pubmed:articleTitle | Recent advances in the management of cryptococcal meningitis in patients with AIDS. | lld:pubmed |
| pubmed-article:8722838 | pubmed:affiliation | Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA. | lld:pubmed |
| pubmed-article:8722838 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8722838 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8722838 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8722838 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8722838 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8722838 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8722838 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8722838 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8722838 | lld:pubmed |
